Medicilon's preclinical research services consist of three major parts: pharmacokinetics, disease models and drug safety evaluation. Our preclinical research services cover design, in vivo studies, sample analysis, data analysis, IACUC review, and the preparation of regulatory application materials. ...
We can take your biologic drug from research through development to FDA regulatory submission. Over 15 years of industry-leading global Scientific Expertise supporting the widest breadth of biologics’ clinical trials with PK/TK, ADA, NAb and biomarker assays and sample analyses. Versatile performance...
The U.S. Food and Drug Administration (FDA) has also stepped in; this past August, it authorized the marketing of new tobacco products through the pre-market tobacco application (PMTA), requiring manufacturers to register and rigorously test new products. As regulations continue to evolve, the...
The proved biosafety of TPSe NPs provides a certain guarantee for its further application in anti-tumor ther- apy. To further confirm the in vivo biological security of TPSe NPs, examination of H&E staining of major organs and hematology markers were performed after the indi- cated therapy....
Immunotherapies have revolutionized cancer treatment modalities; however, predicting clinical response accurately and reliably remains challenging. Neoantigen load is considered as a fundamental genetic determinant of therapeutic response. However, only
We first validated the application of CMS classification to the analysis of RNA Sequencing data from 558 primary CRC tumors in The Cancer Genome Atlas (TCGA)17, which verified the expected frequencies of CMS subtypes (Fig. 2a). We then applied the single-sample CMS classifier to the analysis ...
Cisco UCS solution implementing Red Hat Enterprise Linux OpenStack Platform provides a very simplistic yet fully integrated and validated infrastructure to deploy VMs in various sizes to suit your application needs. Cisco Unified Computing System (UCS) is a next-generation data center platform that uni...
Some highlights of this study should be emphasized, such as larger sample size, verification of EC and pan-cancer cohort, the application of abundant genetic data and comprehensive clinical information. However, some limitations should be acknowledged. Our results were based on online databases and ...
The sample size calculation is based on the primary aim of comparing biologically verified 7-day PPA between the QT group and the WQ group at the 1-month follow-up. We used the following assumptions: (1) significance level of 0.05 for a two-sided test; (2) statistical power of 90%; ...
i Comparison of sample-wise mRNA–protein correlations across tumors with different TNM staging. P-values are calculated with ANOVA test. For the boxplot: line in the box indicates the median; box borders correspond with the first and third quartiles (25th and 75th percentiles); whiskers ...